Elshamy WM - Search Results

1

BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells.

Shimizu Y, Mullins N, Blanchard Z, Elshamy WM. Shimizu Y, et al. Among authors: elshamy wm. Oncotarget. 2012 Mar;3(3):299-313. doi: 10.18632/oncotarget.462. Oncotarget. 2012. PMID: 22431556 Free PMC article.

2

BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.

Paul BT, Blanchard Z, Ridgway M, ElShamy WM. Paul BT, et al. Among authors: elshamy wm. Oncogene. 2015 Jun 4;34(23):3036-52. doi: 10.1038/onc.2014.237. Epub 2014 Aug 18. Oncogene. 2015. PMID: 25132263

3

Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells.

Gardner L, Malik R, Shimizu Y, Mullins N, ElShamy WM. Gardner L, et al. Among authors: elshamy wm. Breast Cancer Res. 2011 May 19;13(3):R53. doi: 10.1186/bcr2884. Breast Cancer Res. 2011. PMID: 21595939 Free PMC article.

4

Geminin overexpression induces mammary tumors via suppressing cytokinesis.

Blanchard Z, Malik R, Mullins N, Maric C, Luk H, Horio D, Hernandez B, Killeen J, Elshamy WM. Blanchard Z, et al. Among authors: elshamy wm. Oncotarget. 2011 Dec;2(12):1011-27. doi: 10.18632/oncotarget.363. Oncotarget. 2011. PMID: 22184288 Free PMC article.

5

BRCA1-IRIS overexpression promotes formation of aggressive breast cancers.

Shimizu Y, Luk H, Horio D, Miron P, Griswold M, Iglehart D, Hernandez B, Killeen J, ElShamy WM. Shimizu Y, et al. Among authors: elshamy wm. PLoS One. 2012;7(4):e34102. doi: 10.1371/journal.pone.0034102. Epub 2012 Apr 12. PLoS One. 2012. PMID: 22511931 Free PMC article.

6

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.

Blanchard Z, Paul BT, Craft B, ElShamy WM. Blanchard Z, et al. Among authors: elshamy wm. Breast Cancer Res. 2015 Jan 13;17(1):5. doi: 10.1186/s13058-014-0512-9. Breast Cancer Res. 2015. PMID: 25583261 Free PMC article.

7

Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers.

Ananthula S, Sinha A, El Gassim M, Batth S, Marshall GD Jr, Gardner LH, Shimizu Y, ElShamy WM. Ananthula S, et al. Among authors: elshamy wm. Oncotarget. 2016 Apr 12;7(15):20869-89. doi: 10.18632/oncotarget.8029. Oncotarget. 2016. PMID: 26989079 Free PMC article.

8

BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.

Chock KL, Allison JM, Shimizu Y, ElShamy WM. Chock KL, et al. Among authors: elshamy wm. Cancer Res. 2010 Nov 1;70(21):8782-91. doi: 10.1158/0008-5472.CAN-10-1352. Epub 2010 Oct 12. Cancer Res. 2010. PMID: 20940403

9

Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative.

Blanchard Z, Mullins N, Ellipeddi P, Lage JM, McKinney S, El-Etriby R, Zhang X, Isokpehi R, Hernandez B, Elshamy WM. Blanchard Z, et al. Among authors: elshamy wm. PLoS One. 2014 Apr 30;9(4):e95663. doi: 10.1371/journal.pone.0095663. eCollection 2014. PLoS One. 2014. PMID: 24789045 Free PMC article.

10

BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.

Sinha A, Paul BT, Sullivan LM, Sims H, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM. Sinha A, et al. Among authors: elshamy wm. Oncotarget. 2017 Feb 7;8(6):10114-10135. doi: 10.18632/oncotarget.14357. Oncotarget. 2017. PMID: 28052035 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

41 results

Search Page